Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization

On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.

The decision to discontinue this study is part of a strategic reprioritization of the company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.

Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.

Also Read: Johnson & Johnson’s Erleada Shows Improved Overall Survival In ...

Full story available on Benzinga.com